AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

According to results from the OlympiA Phase III trial, published in The New England Journal of Medicine and in line for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 6, the drug demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment setting.

In the overall trial population of patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, data showed Lynparza cut the risk of invasive breast cancer recurrences, second cancers or death by 42%.

At three years, 85.9% of patients treated with Lynparza remained alive and free of invasive breast cancer and second cancers versus 77.1% on placebo.

“While there have been great strides in the early treatment of breast cancer, the fear of cancer returning is still at the forefront of patients’ minds,” commented Sue Friedman, executive director, Facing Our Risk of Cancer Empowered (FORCE) and member of the OlympiA trial steering committee. “New targeted treatment approaches are needed in the adjuvant setting that can help keep cancer and that fear at bay.”

Dave Fredrickson, executive vice president, Oncology Business Unit, at AZ, said: “This is the first time that any medicine targeting a BRCA mutation has demonstrated the potential to change the course of early-stage breast cancer and offer hope for a cure. By providing a treatment which significantly reduces the risk of breast cancer returning in these high-risk patients, we hope Lynparza will set a new benchmark demonstrating sustained clinical benefit. “We are working with regulatory authorities to bring Lynparza to these patients as quickly as possible.”

Roy Baynes, senior vice president and head of Global Clinical Development, chief medical officer, MSD Research Laboratories, also noted that the data “support the importance of testing at diagnosis for BRCA1/2 mutations, which are actionable biomarkers that can help identify patients with early breast cancer who may be eligible for adjuvant treatment with Lynparza.”

An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.

Reference:
https://www.pharmatimes.com/news/lynparza_shows_promise_in_preventing_cancer_recurrence_1371212

More News
Generic Agrochemicals in India Poised for a Bonanza: 22 Molecules Coming Off Patent by 2030
News · 04/10/2021

The fact that 22 such molecules are going to come out of their patent period will substantially expand the offerings of the Indian companies to people at home and abroad alike and may help fetch extra revenue.

READ MORE
SARS-CoV-2 is not a direct food safety concern… Neither food nor food packaging is a pathway for the spread of COVID-19, says FAO
News · 04/10/2021

“Current data indicates that neither food nor food packaging is a pathway for the spread of viruses causing respiratory illnesses, including SARS-CoV-2,” according to a new guidance document from the United Nations’ Food and Agriculture Organization (FAO): “In other words, SARS-CoV-2 is not a direct food safety concern.”

READ MORE
Why US is pushing India to restart Covid vaccine exports
News · 16/09/2021

The United States has been pushing India to restart vaccine exports as it looks to stem the global spread of the Covid pandemic.

READ MORE
Quess Corp launches new vertical to transform healthcare services in India
News · 01/09/2021

Quess Corp, India’s leading business services provider, announced the launch of its new healthcare vertical to address the shortage of healthcare professionals.

READ MORE
China’s Golden Week to trigger new round of void sailings
News · 01/09/2021

The shippers are in for struggle yet another time, with the market buzzing in speculations of liners planning of ‘blank sailing’ during China’s Golden Week holiday in early October to extract maximised profits.

READ MORE
Israel’s COVID-19 vaccine boosters show signs of taming delta variant of coronavirus
News · 01/09/2021

Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country’s high infection and severe illness rates fuelled by the fast-spreading delta variant, officials and scientists say.

READ MORE
Blood test can detect more than 50 types of cancer
News · 16/08/2021

Researchers have developed a blood test able to detect more than 50 types of cancer that is accurate enough to be used nationally as a multi-cancer screening test in those at higher risk of the disease, including those aged over 50 with no symptoms.

READ MORE
NUTRICOSMETICS: A Blooming Global Market
News · 16/08/2021

Nutricosmetic is the point at which nutrition and cosmetics meet. The term encompasses the beneficial effects on beauty resulting from consuming nutrients through the use of food supplements.

READ MORE
Amidation of Light Alkanes – High-end Derivatives directly from Natural Gas
News · 16/08/2021

At Last: Separated and Freshly Bound –
Amidation of light alkanes

READ MORE